Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Rohto Pharmaceutical Co ( (JP:4527) ) has provided an update.
Rohto Pharmaceutical Co., Ltd. announced the issuance of Zero Coupon Convertible Bonds due 2032 to secure low-cost funding amidst rising interest rates. The proceeds, approximately ¥25 billion, will be used to strengthen research and development in core and expansion areas, repay borrowings, and repurchase shares, aiming to enhance profitability and enterprise value while maintaining financial stability.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on over-the-counter (OTC) drugs and skincare products. The company is expanding into new business domains such as regenerative medicine and contract development and manufacturing (CDMO), with a strong emphasis on research and product development.
YTD Price Performance: -14.49%
Average Trading Volume: 5,490
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.54B
For a thorough assessment of 4527 stock, go to TipRanks’ Stock Analysis page.